Table 1.
Patient characteristics
| Level 1 (n = 6) | Level 2 (n = 12) | Total (n = 18) | |
|---|---|---|---|
| Age, years | 63.0 (7.8) | 50.3 (11.9) | 54.5 (12.2) |
| Body weight, kg | 49.8 (6.1) | 58.1 (9.0) | 55.4 (8.9) |
| ECOG performance status | |||
| 0 | 6 (100.0) | 8 (66.7) | 14 (77.8) |
| 1 | 0 | 4 (33.3) | 4 (22.2) |
| Primary tumor location and histology | |||
| Ovary | |||
| Clear cell carcinoma | 1 (16.7) | 2 (16.7) | 3 (16.7) |
| Mixed epithelial tumor | 0 | 1 (8.3) | 1 (5.6) |
| Papillary/serous | 1 (16.7) | 9 (75.0) | 10 (55.6) |
| Peritoneum | 2 (33.3) | 0 | 2 (11.1) |
| Fallopian tube | 2 (33.3) | 0 | 2 (11.1) |
| Histological grade | |||
| Grade 3 | 1 (16.7) | 3 (25.0) | 4 (22.2) |
| Unknown | 5 (83.3) | 9 (75.0) | 14 (77.8) |
| Stage | |||
| III | 5 (83.3) | 6 (50.0) | 11 (61.1) |
| IV | 1 (16.7) | 5 (41.7) | 6 (33.3) |
| Unknown | 0 | 1 (8.3) | 1 (5.6) |
| Platinum-free interval, months | |||
| < 6 | 4 (66.7) | 11 (91.7) | 15 (83.3) |
| 6– < 12 | 2 (33.3) | 1 (8.3) | 3 (16.7) |
| Number of prior treatment regimens | |||
| 1 | 2 (33.3) | 1 (8.3) | 3 (16.7) |
| 2 | 1 (16.7) | 3 (25.0) | 4 (22.2) |
| 3 | 2 (33.3) | 3 (25.0) | 5 (27.8) |
| ≥ 4 | 1 (16.7) | 5 (41.7) | 6 (33.3) |
| PLD as prior treatment | 0 | 4 (33.3) | 4 (22.2) |
Categorical variables are expressed as n (%) and continuous variables as mean (SD)
ECOG Eastern Cooperative Oncology Group, PLD pegylated liposomal doxorubicin, SD standard deviation